French study tracks daily life changes in MS patients on newer drug

NCT ID NCT06157086

Ongoing Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 302 adults with multiple sclerosis in France who are starting the drug ofatumumab as part of their normal care. Researchers will measure how patients' quality of life changes after 12 months using a special questionnaire. The goal is to understand real-world benefits and satisfaction, not to test the drug itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS, MS

Contacts and locations

Locations

Novartis Investigative Site

Angers, France, 49933, France
Novartis Investigative Site

Paris, France, F-75571, France
Novartis Investigative Site

Agen, 47923, France
Novartis Investigative Site

Altkirch, 68130, France
Novartis Investigative Site

Amiens, 80054, France
Novartis Investigative Site

Belfort, 90000, France
Novartis Investigative Site

Bordeaux, 33076, France
Novartis Investigative Site

Boulogne-sur-Mer, 62200, France
Novartis Investigative Site

Brest, 29200, France
Novartis Investigative Site

Brunstatt Didenheim, 68350, France
Novartis Investigative Site

Cahors, 46000, France
Novartis Investigative Site

Chambéry, 73000, France
Novartis Investigative Site

Cherbourg Octeville, 50102, France
Novartis Investigative Site

Compiègne, 60200, France
Novartis Investigative Site

Contamine-sur-Arve, 74130, France
Novartis Investigative Site

Dax, 40107, France
Novartis Investigative Site

Gonesse, 95503, France
Novartis Investigative Site

Le Bouscat, 33110, France
Novartis Investigative Site

Le Coudray, 28630, France
Novartis Investigative Site

Lens, 62307, France
Novartis Investigative Site

Libourne, 33505, France
Novartis Investigative Site

Lille, 59000, France
Novartis Investigative Site

Lille, 59037, France
Novartis Investigative Site

Lyon, 69008, France
Novartis Investigative Site

Lyon, 69275, France
Novartis Investigative Site

Mantes-la-Jolie, 78200, France
Novartis Investigative Site

Marseille 01, 13001, France
Novartis Investigative Site

Meaux, 77104, France
Novartis Investigative Site

Metz-Tessy, 74374, France
Novartis Investigative Site

Mont-de-Marsan, 40024, France
Novartis Investigative Site

Montluçon, 03100, France
Novartis Investigative Site

Montpellier, 34090, France
Novartis Investigative Site

Mulhouse, 68100, France
Novartis Investigative Site

Nîmes, 30029, France
Novartis Investigative Site

Orsay, 91400, France
Novartis Investigative Site

Paris, 75014, France
Novartis Investigative Site

Paris, 75017, France
Novartis Investigative Site

Poissy, 78303, France
Novartis Investigative Site

Quint-Fonsegrives, 31130, France
Novartis Investigative Site

Reims, 51092, France
Novartis Investigative Site

Rennes, 35033, France
Novartis Investigative Site

Saverne, 67700, France
Novartis Investigative Site

Sélestat, 67600, France
Novartis Investigative Site

Strasbourg, 67000, France
Novartis Investigative Site

Toulouse, 31059, France
Novartis Investigative Site

Tours, 37044, France
Novartis Investigative Site

Valence, 26953, France
Novartis Investigative Site

Vannes, 56017, France
Novartis Investigative Site

Villeurbanne, 69100, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.